Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Top Cited Papers
- 5 April 2010
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (12), 4561-4584
- https://doi.org/10.1021/jm100012m
Abstract
No abstract availableThis publication has 110 references indexed in Scilit:
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- PolyADP‐ribosylation and cancerCancer Science, 2007
- INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicinInvestigational New Drugs, 2007
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP‐ribose) polymerase‐1/2 inhibitorsFEBS Letters, 2005
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- GPI 6150 Prevents H2O2 Cytotoxicity by Inhibiting Poly(ADP-ribose) PolymeraseBiochemical and Biophysical Research Communications, 2000
- The role of poly(ADP-ribose) synthesis in toxicity and repair of DNA damagePharmacology & Therapeutics, 1985